These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1039 related items for PubMed ID: 18157017

  • 1. Analysis and characterization of antitumor T-cell response after administration of dendritic cells loaded with allogeneic tumor lysate to metastatic melanoma patients.
    Bercovici N, Haicheur N, Massicard S, Vernel-Pauillac F, Adotevi O, Landais D, Gorin I, Robert C, Prince HM, Grob JJ, Leccia MT, Lesimple T, Wijdenes J, Bartholeyns J, Fridman WH, Salcedo M, Ferries E, Tartour E.
    J Immunother; 2008 Jan; 31(1):101-12. PubMed ID: 18157017
    [Abstract] [Full Text] [Related]

  • 2. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.
    Palucka AK, Ueno H, Connolly J, Kerneis-Norvell F, Blanck JP, Johnston DA, Fay J, Banchereau J.
    J Immunother; 2006 Jan; 29(5):545-57. PubMed ID: 16971810
    [Abstract] [Full Text] [Related]

  • 3. Naturally occurring human lymphocyte antigen-A2 restricted CD8+ T-cell response to the cancer testis antigen NY-ESO-1 in melanoma patients.
    Valmori D, Dutoit V, Liénard D, Rimoldi D, Pittet MJ, Champagne P, Ellefsen K, Sahin U, Speiser D, Lejeune F, Cerottini JC, Romero P.
    Cancer Res; 2000 Aug 15; 60(16):4499-506. PubMed ID: 10969798
    [Abstract] [Full Text] [Related]

  • 4. In vitro induction of tumor-specific human lymphocyte antigen class I-restricted CD8 cytotoxic T lymphocytes by ovarian tumor antigen-pulsed autologous dendritic cells from patients with advanced ovarian cancer.
    Santin AD, Hermonat PL, Ravaggi A, Bellone S, Pecorelli S, Cannon MJ, Parham GP.
    Am J Obstet Gynecol; 2000 Sep 15; 183(3):601-9. PubMed ID: 10992180
    [Abstract] [Full Text] [Related]

  • 5. HPV16/18 E7-pulsed dendritic cell vaccination in cervical cancer patients with recurrent disease refractory to standard treatment modalities.
    Santin AD, Bellone S, Palmieri M, Ravaggi A, Romani C, Tassi R, Roman JJ, Burnett A, Pecorelli S, Cannon MJ.
    Gynecol Oncol; 2006 Mar 15; 100(3):469-78. PubMed ID: 16249018
    [Abstract] [Full Text] [Related]

  • 6. IFN-gamma responses in peptide-treated melanoma patients measured by an ELISPOT assay using allogeneic dendritic cells.
    Gabrielsson S, Brichard V, Dhellin O, Dorval T, Bonnerot C.
    Anticancer Res; 2004 Mar 15; 24(1):171-7. PubMed ID: 15015594
    [Abstract] [Full Text] [Related]

  • 7. Targeting CD4(+) T-helper cells improves the induction of antitumor responses in dendritic cell-based vaccination.
    Aarntzen EH, De Vries IJ, Lesterhuis WJ, Schuurhuis D, Jacobs JF, Bol K, Schreibelt G, Mus R, De Wilt JH, Haanen JB, Schadendorf D, Croockewit A, Blokx WA, Van Rossum MM, Kwok WW, Adema GJ, Punt CJ, Figdor CG.
    Cancer Res; 2013 Jan 01; 73(1):19-29. PubMed ID: 23087058
    [Abstract] [Full Text] [Related]

  • 8. Enzyme-linked immunospot, cytokine flow cytometry, and tetramers in the detection of T-cell responses to a dendritic cell-based multipeptide vaccine in patients with melanoma.
    Whiteside TL, Zhao Y, Tsukishiro T, Elder EM, Gooding W, Baar J.
    Clin Cancer Res; 2003 Feb 01; 9(2):641-9. PubMed ID: 12576430
    [Abstract] [Full Text] [Related]

  • 9. Glioblastoma patients exhibit circulating tumor-specific CD8+ T cells.
    Tang J, Flomenberg P, Harshyne L, Kenyon L, Andrews DW.
    Clin Cancer Res; 2005 Jul 15; 11(14):5292-9. PubMed ID: 16033848
    [Abstract] [Full Text] [Related]

  • 10. Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma.
    Yu JS, Liu G, Ying H, Yong WH, Black KL, Wheeler CJ.
    Cancer Res; 2004 Jul 15; 64(14):4973-9. PubMed ID: 15256471
    [Abstract] [Full Text] [Related]

  • 11. alpha-fetoprotein and interleukin-18 gene-modified dendritic cells effectively stimulate specific type-1 CD4- and CD8-mediated T-Cell response from hepatocellular carcinoma patients in Vitro.
    Cao DY, Yang JY, Dou KF, Ma LY, Teng ZH.
    Hum Immunol; 2007 May 15; 68(5):334-41. PubMed ID: 17462500
    [Abstract] [Full Text] [Related]

  • 12. Dendritoma vaccination combined with low dose interleukin-2 in metastatic melanoma patients induced immunological and clinical responses.
    Wei Y, Sticca RP, Holmes LM, Burgin KE, Li J, Williamson J, Evans L, Smith SJ, Stephenson JJ, Wagner TE.
    Int J Oncol; 2006 Mar 15; 28(3):585-93. PubMed ID: 16465362
    [Abstract] [Full Text] [Related]

  • 13. In vivo vaccination with tumor cell lysate plus CpG oligodeoxynucleotides eradicates murine glioblastoma.
    Wu A, Oh S, Gharagozlou S, Vedi RN, Ericson K, Low WC, Chen W, Ohlfest JR.
    J Immunother; 2007 Mar 15; 30(8):789-97. PubMed ID: 18049330
    [Abstract] [Full Text] [Related]

  • 14. Generation of CD8+ and CD4+ T-cell response to dendritic cells genetically engineered to express the MART-1/Melan-A gene.
    Pérez-Díez A, Butterfield LH, Li L, Chakraborty NG, Economou JS, Mukherji B.
    Cancer Res; 1998 Dec 01; 58(23):5305-9. PubMed ID: 9850054
    [Abstract] [Full Text] [Related]

  • 15. Boosting T cell-mediated immunity to tyrosinase by vaccinia virus-transduced, CD34(+)-derived dendritic cell vaccination: a phase I trial in metastatic melanoma.
    Di Nicola M, Carlo-Stella C, Mortarini R, Baldassari P, Guidetti A, Gallino GF, Del Vecchio M, Ravagnani F, Magni M, Chaplin P, Cascinelli N, Parmiani G, Gianni AM, Anichini A.
    Clin Cancer Res; 2004 Aug 15; 10(16):5381-90. PubMed ID: 15328176
    [Abstract] [Full Text] [Related]

  • 16. Ex vivo host response to gastrointestinal cancer cells presented by autologous dendritic cells.
    Galetto A, Contarini M, Sapino A, Cassoni P, Consalvo E, Forno S, Pezzi C, Barnaba V, Mussa A, Matera L.
    J Surg Res; 2001 Sep 15; 100(1):32-8. PubMed ID: 11516202
    [Abstract] [Full Text] [Related]

  • 17. Immunization with Melan-A peptide-pulsed peripheral blood mononuclear cells plus recombinant human interleukin-12 induces clinical activity and T-cell responses in advanced melanoma.
    Peterson AC, Harlin H, Gajewski TF.
    J Clin Oncol; 2003 Jun 15; 21(12):2342-8. PubMed ID: 12805336
    [Abstract] [Full Text] [Related]

  • 18. Strategies for antigen loading of dendritic cells to enhance the antitumor immune response.
    Strome SE, Voss S, Wilcox R, Wakefield TL, Tamada K, Flies D, Chapoval A, Lu J, Kasperbauer JL, Padley D, Vile R, Gastineau D, Wettstein P, Chen L.
    Cancer Res; 2002 Mar 15; 62(6):1884-9. PubMed ID: 11912169
    [Abstract] [Full Text] [Related]

  • 19. Ex vivo detectable human CD8 T-cell responses to cancer-testis antigens.
    Baumgaertner P, Rufer N, Devevre E, Derre L, Rimoldi D, Geldhof C, Voelter V, Liénard D, Romero P, Speiser DE.
    Cancer Res; 2006 Feb 15; 66(4):1912-6. PubMed ID: 16488988
    [Abstract] [Full Text] [Related]

  • 20. Immune responses to a class II helper peptide epitope in patients with stage III/IV resected melanoma.
    Wong R, Lau R, Chang J, Kuus-Reichel T, Brichard V, Bruck C, Weber J.
    Clin Cancer Res; 2004 Aug 01; 10(15):5004-13. PubMed ID: 15297401
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 52.